The cadherin–catenin complex in laryngeal squamous cell carcinoma

Abstract

Abnormal Wnt signaling and impaired cell–cell adhesion due to abnormal E-cadherin and β-catenin function have been implicated in many cancers, but have not been fully explored in laryngeal squamous cell carcinoma. In this study, β-catenin cellular location and E-cadherin expression levels were analyzed in 16 laryngeal squamous cell carcinomas (LSCCs) (9 glottic and 7 supraglottic) and 11 samples of non-tumoral inflammatory larynx tissue, using immunohistochemical methods. All non-tumoral tissues showed equally strong membranous expression of β-catenin, while cytoplasmic expression was found in only 3 of the 11 samples. By contrast, whereas 8/9 glottic LSCCs exhibited only membranous expression of β-catenin, 6/7 supraglottic LSCCs displayed both membranous and cytoplasmic expression (p = 0.003). Strong E-cadherin staining was observed in 9/11 non-tumoral tissues and 7/9 glottic LSCCs, whereas 4/7 supraglottic LSCCs exhibited weak expression. Reduced membrane expression of E-cadherin and cytoplasmic retention of β-catenin in supraglottic LSCC seems to be related with more aggressive biological behavior which has been described in clinical studies. Further research is required to clarify the involvement of β-catenin in the mechanism associated with malignant transformation in laryngeal tissues.

Introduction

Laryngeal squamous cell carcinoma (LSCC), one of the most common tumors of the head and neck, occurs mainly in adult males who abuse tobacco and alcohol, and is characterized by squamous differentiation. Although early-stage glottic cancer has a favorable prognosis, with 5-year survival rates of over 70% [1], many supraglottic and subglottic cancers are not diagnosed until severe signs develop, by which time the 5-year survival rate has dropped to less than 50%. Locoregional recurrence, cervical lymph node metastases and distant metastases are the factors significantly affecting prognosis in LSCC patients [2]. The recognition and identification of tumor markers associated with recurrence and/or metastasis are key elements in predicting the biological behavior of the tumor and deciding on the most appropriate therapeutic strategy.

β-Catenin, originally identified on the basis of its association with cadherin adhesion molecules, is now widely recognized as an essential element in the wingless-Wnt signaling cascade [3]. Wnt proteins bind to receptors belonging to the Frizzled (Fz) family. In the canonical pathway, β-catenin activates an intracellular cascade that involves the inhibition of glycogen synthase kinase 3β (GSK 3β) and the adenomatous polyposis coli (APC) protein, ultimately resulting in the abnormal stabilization of cytoplasmic β-catenin and its translocation to the nucleus. Nuclear β-catenin then interacts with various transcription factors to cause cellular proliferation and differentiation. Abnormal Wnt signaling has been implicated in a number of cancers including head and neck carcinoma, lung cancer, colorectal cancer, melanoma, and leukemia [4]. Although the role of the Wnt pathway in nasopharyngeal cancer has not been fully explored, there is abundant evidence that aberrant Wnt signaling is involved in its development [5–7].

Cytoplasmic β-catenin plays a major role in the normal cell by binding to the intracellular domain of E-cadherin to maintain cell–cell adhesion. The expression of E-cadherin has been found to be downregulated in many cancers [8–12] including nasopharyngeal carcinoma [5, 12]. It has been suggested that E-cadherin downregulation may play a role in tumor progression and metastasis.

Strong β-catenin expression is significantly associated with invasion and metastasis of carcinomas of the head and neck, esophagus, stomach, colon, liver, lung, breast, female genitalia, prostate, bladder, and pancreas, as well as melanomas [11, 14–18]. Recently, several studies have pointed the considerable involvement of β-catenin not only in malignant transformation but also in the regulation of physiological functions, and expression of this adhesion molecule in human nasopharyngeal carcinoma has been investigated [19, 20]; however, it has not yet been thoroughly explored in LSCC.

The present study sought to examine the possible role of molecular cell–cell adhesion mechanisms in the oncogenesis and/or cytodifferentiation of laryngeal squamous cell carcinoma. Expression of β-catenin and E-cadherin was determined in paraffin-embedded LSCC tissues and in non-tumoral tissues from patients with inflammatory diseases of the larynx.

Materials and methods

Patient samples and histological classification

Sixteen patients with well-differentiated LSCCs (12 men and 4 women, aged 46–72) were diagnosed at the Infanta Luisa Hospital in Seville (Spain). The study was approved by the Ethical Committee and informed consent was obtained from all the participants. LSCC samples and non-tumoral inflammatory tissue samples (control group: six male and five female patients aged 19–97) were routinely fixed in 10% buffered formalin and embedded in paraffin. Histological evaluation was performed by two pathologists using hematoxylin/eosin staining.

All patients presented with non-metastatic disease at tumor diagnosis and survived disease-free for at least 5 years.

Immunohistochemical staining

Paraffin-embedded tissue blocks from 16 LSCC patients and 11 patients with non-tumoral inflammation were cut into 3 μm sections and placed on APES pre-coated slides. Sections were deparaffinized in xylene and rehydrated in alcohol and water. Immunohistochemistry (IHC) was performed using the peroxidase-antiperoxidase technique after microwave antigen retrieval procedure. Antibodies for β-catenin and E-cadherin were purchased from ZYMED Laboratories (ZYMED Laboratories, San Francisco, CA, USA). Antibodies against β-catenin (1:200) and E-cadherin (1:100) were overlaid on NPC tissue array sections and incubated overnight at 4°C. Secondary antibody incubation was performed at room temperature for 30 min. Two pathologists independently scored the results of immunohistochemical staining, and any discrepant scores were reexamined to arrive at a consensus score.

For β-catenin, +++ indicates positive staining in membrane, cytoplasm and nucleus; positive staining in membrane and cytoplasm (++); positive staining in membrane (+). For E-cadherin, + indicates 0–50% staining cells, i.e., low staining: ++ 50–100% staining cells, i.e., strong or high staining. Desmoid tumor tissues were used as positive control, and negative controls were obtained by replacing primary antibodies with PBS.

Statistical analysis

Statistical analysis was performed using the SPSS for Windows software package, release 15.0 (SPSS Inc., Chicago, IL, USA). Associations between antigen immunoreactivity, histopathological findings and clinical data were evaluated by the Chi-square test. Differences were regarded as significant if p < 0.05.

Results

Clinical data

Patient clinical data and underlying pathologies are summarized in Table 1. No correlation was found between clinical data (age, sex, location) or mitotic numbers.

Table 1.

Clinical data and diagnosis

	Age (years)	Sex (F/M)	Diagnostic (localization)
1	19	M	NT inflammation of larynx
2	33	F	NT inflammation of larynx
3	54	M	NT inflammation of larynx
4	67	M	NT inflammation of larynx
5	50	F	NT inflammation of larynx
6	58	M	NT inflammation of larynx
7	35	F	NT inflammation of larynx
8	56	M	NT inflammation of larynx
9	44	F	NT inflammation of larynx
10	33	F	NT inflammation of larynx
11	34	M	NT inflammation of larynx
12	55	F	Glottic LSCC
13	54	M	Supraglottic LSCC
14	49	M	Supraglottic LSCC
15	48	M	Glottic LSCC
16	64	M	Glottic LSCC
17	48	M	Supraglottic LSCC
18	51	M	Glottic LSCC
19	57	F	Glottic LSCC
20	50	F	Supraglottic LSCC
21	61	M	Glottic LSCC
22	57	M	Supraglottic LSCC
23	60	F	Glottic LSCC
24	62	M	Glottic LSCC
25	71	M	Glottic LSCC
26	63	M	Supraglottic LSCC
27	72	M	Supraglottic LSCC

F female, M male, NT Non-tumoral

Immunohistochemical analysis

Protein expression was analyzed by immunohistochemical staining for anti-β-catenin and anti-E-cadherin antibodies in LSCCs and non-tumoral tissues. The 11 non-tumoral tissues showed equally strong membranous expression of β-catenin, which was detected in both cytoplasm and membrane in only 23% of cases (3/11). In contrast, 8/9 (89%) glottic LSCCs exhibited only membranous expression of β-catenin, whereas 6/7 (86%) supraglottic LSCCs displayed both membranous and cytoplasmic expression (p = 0.003; Table 2; Fig. 1).

Table 2.

β-Catenin: cellular localization

	No. of cases	Nucleusa	Cytoplasm and membranea	Membranea	P value (Chi-square test)
Non-tumoral tissues of larynx	11	0	3 (27%)	8 (73%)	0.384
LSCC tissues	16	0	7 (44%)	9 (56%)
Glottic	9	0	1 (11%)	8 (89%)	0.003
Supraglottic	7	0	6 (86%)	1 (14%)

^aThe values are no. (%)

Fig. 1.

Immunohistochemical staining for β-catenin expression. Membranous expression of β-catenin. a Non tumoral tissue (×40). b Glottic laryngeal squamous cell carcinoma (×40). Membranous and cytoplasmic expression of β-catenin. c Supraglottic laryngeal squamous cell carcinoma (×40). d Desmoid tumor (positive control for nuclear β-catenin) (×40)

Strong E-cadherin staining was observed in 9/11 (82%) of non-tumoral tissues, and weak expression in 2/11 (18%). Strong expression was observed in 10/16 (62%) LSCC tissues (Fig. 2; Table 3), including 7/9 (77%) glottic LSCCs, whereas in 4/7 (57%) supraglottic LSCCs, expression was weak (Table 3); however no significant association was found (Fig. 2).

Fig. 2.

Immunohistochemical staining for E-cadherin expression. Strong staining: a (×40) Non tumoral tissue. b (×40) Glottic laryngeal squamous cell carcinoma. Low staining: c (×40) Supraglottic laryngeal squamous cell carcinoma

Table 3.

E-Cadherin expression

	No. of cases	Low E-cadherin expressiona	High E-cadherin expressiona	P value (Chi-square test)
Non-tumoral tissues of larynx	11	2 (18%)	9 (82%)	0.250
LSCC tissues	16	6 (37.5%)	10 (62.5%)
Glottic	9	2 (22%)	7 (78%)	0.152
Supraglottic	7	4 (57%)	3 (43%)

^aThe values are no. (%)

Discussion

β-Catenin contributes both to cell–cell adhesion and to the Wnt signaling pathway [21, 22]. The present study noted no alteration in β-catenin protein expression between LSCCs and non-tumoral tissues. However, differences were found in the cellular location of β-catenin expression: in 89% of glottic LSCCs, β-catenin was expressed only in the cell membrane, a percentage similar to that found for non-tumoral larynx tissue (73%), whereas in 86% of supraglottic LSCCs, β-catenin was expressed both in membrane and in cytoplasm. Similar findings have recently been reported by Goiliomus et al. [25] in a series of 97 LSCCs comprising 63 glottic and 34 supraglottic carcinomas. The cadherin–catenin complex is a group of membrane proteins that are important in cell–cell adhesion, tumor suppression, cell differentiation and cell migration. Some reports have suggested that downregulated expression of β-catenin might play a role in early and late tumor invasion and metastasis [23, 24]. Downregulation of β-catenin has been found to be closely related to advanced clinical disease and short survival in other head and neck carcinomas, including nasopharyngeral carcinoma [12]. These results suggest that β-catenin may in itself be a major factor for supraglottic LSCC tumor cell invasion and metastasis, and that differences in β-catenin expression between glottic and supraglottic carcinomas may be linked to differences in clinical behavior. Here, β-catenin protein levels were evaluated using inmunohistochemical staining, a semi-quantitative technique enabling assessment of proteins in paraffin-embedded tissues. Further research will evaluate β-catenin expression levels using the Western blot technique, with a view to measure possible alterations in β-catenin protein levels in fresh tissue.

β-Catenin is also involved in the Wnt canonical pathway as a transcriptional activator [21, 22]. The inhibition of glycogen synthase kinase (GSK-3β) and the APC protein ultimately results in the stabilization and nuclear translocation of cytoplastic β-catenin. Finally, nuclear β-catenin interacts with various transcription factors to cause proliferation and differentiation. But further research is required into the link between altered β-catenin levels and the development of supraglottic LSCC. Here, β-catenin was detected in membrane and cytoplasm, but not in the nucleus. Goiliomus et al. [25] in a study of 97 LSCCs, detected nuclear β-catenin in only one sample, perhaps due to differences in tissue processing or to the immunohistochemical staining method used. In the present study, failure to detect nuclear β-catenin suggests that the canonical Wnt pathway may be inactivated in this type of cancer. This cannot be categorically confirmed, since stabilized β-catenin was detected in cytoplasm. Further research is required to determine the possible role of cytoplasmic β-catenin retention in the pathogenesis of LSCC supreglottic and whether the Wnt pathway is activated by these retention, overexpression of its receptors or silencing of its suppressors, and also to investigate the possible activation of the non-canonical Wnt pathway that includes signaling through calcium flux, JNK and heterotrimeric G proteins.

Although none of the LSCC samples expressed Wnt pathway activators such as Wnt-1 and Wnt-5a, strong expression of the inhibitors WIF-1 and Dkk-1 was found in all cases. This would suggest that the Wnt pathway is inactive in this type of tumor. These results enable a preliminary approach to the study of the Wnt pathway in LSCC; future research will analyze the expression of different components of the Wnt pathway using quantitative techniques (Western-blot and real-time PCR), thus overcoming the limitations of immunohistochemical analysis and providing a more accurate view of the activation or inactivation of this signaling pathway.

E-Cadherin is essential for normal cell function, and is downregulated in processes such as wound healing, allowing epithelial cells to move and cover denuded tissue [26]. E-Cadherin, localized to the zonula adherens, complexes with catenins β and γ; β- and γ-catenins in turn bind to γ-catenin which attaches to actin filaments in the cell cytoskeleton [27]. E-Cadherin is thought to act as a tumor suppressor, since it suppresses invasion and metastasis [28]. Low expression of E-cadherin has been shown to predict poor outcome in oral cavity and laryngeal carcinomas [29, 30]. In the present study, strong E-cadherin expression was detected in 82% of non-tumoral tissues and only in 62.5% of glottic and supraglottic LSCCs. In contrast, weak E-cadherin expression was detected in 57% of supraglottic LSCC tissues, while only 22% of glottic LSCCs exhibited weak expression; the remaining 78% displayed strong E-cadherin expression, a percentage similar to that found in non-tumoral tissues. Downregulation of E-cadherin expression in supraglottic LSCC tissues may indicate a greater capacity for invasion and metastasis, and thus account for the distinct clinical behavior of these tumors. Indeed, a positive correlation was observed between E-cadherin expression levels and the presence of lymph node metastasis in supraglottic LSCC tissues [31, 32]. In this respect, several studies have shown that diminished E-cadherin expression is a good predictor of concurrent lymph node metastasis in laryngeal carcinoma and head and neck squamous cell cancer [13, 33–36]. Kurtz et al. [13] noted a correlation between reduced E-cadherin expression and decreased survival rates and vascular invasion in LSCC patients. These findings may be due to mutations of the E-CADHERIN gene [37] or to loss of heterozygosity of that gene [7]. In some cancer cells, aberrant gene promoter methylation of E-cadherin may be responsible for the decreased expression of E-cadherin [33, 34]; future research will investigate E-cadherin expression using quantitative RT-PCR, in order to obtain a clearer view of potential differences between sites, and thus focus on possible epigenetic changes due to promoter hypermethylation in LSCC tissues.

Finally, no association was observed between E-cadherin protein levels and β-catenin localization, although low E-cadherin levels were more common among LSCCs exhibiting cytoplasmic β-catenin (40 vs. 23.5%). Si et al. [5] observed a significant relationship between abnormal E-cadherin and β-catenin expression and clinical stage and lymph-node metastasis, although they do not distinguish between glottic and supraglottic LSCCs. Other studies of head and neck squamous cell carcinomas report loss of membranous E-cadherin and β-catenin expression and increased cytoplasmic expression, irrespective of the primary carcinoma or nodal carcinoma involved [38]. Impairment of cell–cell adhesion is an essential step in the progression from localized malignancy to stromal and vascular invasion and metastatic disease. This impairment is achieved through a variety of mechanisms involving the cadherin/catenin complex [39].

The results obtained here suggest an enhancement of the potential ability of cancer cells to disperse, a preliminary step in local invasion. A better knowledge of the regulation of the cadherin–catenin system is required for the prevention or treatment of laryngeal carcinoma.

In conclusion, reduced membrane expression of E-cadherin and cytoplasmic retention of β-catenin in supraglottic LSCC seems to be related with more aggressive biological behavior which has been described in clinical studies. Further research is required to clarify the involvement of β-catenin in the mechanism associated with malignant transformation in laryngeal tissues.